Stem Cells for Knee Osteoarthritis GMSCL (Guide Mesenchymal Stem Cell Layering) - For Osteoarthritis of Knee. By: Nathan Wei … Continue reading →

Biotechs may be flush with cash, thanks to the ol bullish IPO market and an uptick in venture funding. But startups remainon the lookout for alternative funding models with crowdsourcing front and center. This makes British biotech startup Cell Therapyparticularly interesting,itjustraised 689,246 or a bit over$1 million to launch a stem cell therapy for heart failure. This is one of the highest life sciences-related crowdfunding efforts topped only by Scanadu, whose handheld consumer diagnostic tool raised $1.6 million in Indiegogo. Cell Therapy, which was founded by 2007 Nobel Prize winner Martin Evans, raised the funding on thesite Crowdcube exceeding its goal of 250,000 with backing from nearly 300 investors. It ceded a mere 0.39% in equity to the backers thatinclude investment bankers, hedge fund employees and scientists, CEO Ajan Reginald said. It was very fast and very efficient, Reginaldtold Reuters. We have spent 5 percent of our time on fundraising, which enables me to spend 95 percent of my time on the business. Crowdfunding is increasingly becoming an option for early stage biotechs that want to sidestep the traditional venture-backed approach. On one hand, its a relatively simple means to raise a large amount of seed capital but on the … Continue reading →

Cell Therapy, which is based in the Welsh capital Cardiff, says the medicine has the potential to reduce scarring of the heart muscle caused by a heart attack or failure. Chief executive Ajan Reginald, who was previously at Roche, said crowd funding was a quick way to raise money for final stage trials or commercial launches. Loading article content "It was very fast and very efficient," he said. "We have spent five per cent of our time on fundraising, which enables me to spend 95 per cent of my time on the business." The company's founder Martin Evans shared the 2007 Nobel Prize for medicine for groundbreaking stem cell research. Cell Therapy used website Crowdcube to raise nearly three times its original target from more than 300 investors. Mr Reginald said the backers included investment bankers, hedge fund employees and scientists. "Crowd funding allows investors to look in detail at a company in their own time," he said, adding that some 10,000 investors had seen the pitch. The company plans to publish data from clinical trials of the drug, called Heartcel, next month, before final stage trials with a view to a launch in 2016. Originally posted here: Biotech firm … Continue reading →

* BrainStorm develops cell treatments for neurodegenerative diseases BrainStorm Cell Therapeutics Inc., a biotechnology company in Hackensack, said Monday that it has received patent approval in Israel for its NurOwn technology. NurOwn is self-transplanting adult stem-cell therapy. BrainStorm said it received a notice of allowance from Israel's Patent Office for the rights to methods of producing neurotrophic, factor-secreting cells derived from mesenchymal stem cells and methods of using those cells for the treatment of neurologic diseases. The patent is held jointly with Tel Aviv University's technology transfer company, Ramot. "This patent allowance in Israel further extends the geographic reach of our intellectual property, as we already have received similar claims in the U.S., with additional filings pending elsewhere," said BrainStorm's chief executive officer, Tony Fiorino, in a statement. BrainStorm develops adult cell therapies from bone marrow cells to treat neurodegenerative diseases. The business also has operations in Israel. Email: anzidei@northjersey.com See the original post here: Hackensack biotech company gets Israeli patent for therapy … Continue reading →